September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
|Articles|December 14, 2021
Daily Medication Pearl: Gabapentin Enacarbil (Horizant)
Author(s)Saro Arakelians, PharmD
Gabapentin enacarbil treats moderate-to-severe primary restless leg syndrome and postherpetic neuralgia.
Advertisement
Medication Pearl of the Day: Gabapentin Enacarbil (Horizant)
Indication: Gabapentin enacarbil is indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and the management of postherpetic neuralgia (PHN) in adults.
Insight:
- Dosing: For RLS, 600 mg once daily taken at about 5 pm. A dose of 1200 mg once daily provided no additional benefit compared with the 600-mg dose, but caused an increase in adverse reactions.
- Dosage forms: Extended-release tablets 300 mg and 600 mg.
- Adverse events (AEs): Most common AEs (≥10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.
- Mechanism of action: Gabapentin prevents pain-related responses in several models of neuropathic pain in humans.
- Manufacturer: Arbor Pharmaceuticals
Sources:
Advertisement
Related to this article
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What the 2025-2030 Dietary Guidelines Mean for Heart Health
2
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5